nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepivacaine—Meningism—Thiotepa—urinary bladder cancer	0.0645	0.0659	CcSEcCtD
Mepivacaine—Cranial nerve paralysis—Methotrexate—urinary bladder cancer	0.0417	0.0427	CcSEcCtD
Mepivacaine—Urinary incontinence—Valrubicin—urinary bladder cancer	0.0312	0.0319	CcSEcCtD
Mepivacaine—Meningism—Methotrexate—urinary bladder cancer	0.0277	0.0284	CcSEcCtD
Mepivacaine—Respiratory arrest—Thiotepa—urinary bladder cancer	0.0254	0.026	CcSEcCtD
Mepivacaine—Urinary retention—Valrubicin—urinary bladder cancer	0.0223	0.0228	CcSEcCtD
Mepivacaine—Back pain—Valrubicin—urinary bladder cancer	0.0137	0.0139	CcSEcCtD
Mepivacaine—Drowsiness—Mitomycin—urinary bladder cancer	0.0124	0.0127	CcSEcCtD
Mepivacaine—Erythema—Mitomycin—urinary bladder cancer	0.00972	0.00993	CcSEcCtD
Mepivacaine—Apnoea—Etoposide—urinary bladder cancer	0.00948	0.00968	CcSEcCtD
Mepivacaine—Vision blurred—Mitomycin—urinary bladder cancer	0.00916	0.00936	CcSEcCtD
Mepivacaine—Body temperature increased—Valrubicin—urinary bladder cancer	0.0091	0.0093	CcSEcCtD
Mepivacaine—Syncope—Mitomycin—urinary bladder cancer	0.00872	0.00891	CcSEcCtD
Mepivacaine—Loss of consciousness—Mitomycin—urinary bladder cancer	0.00854	0.00873	CcSEcCtD
Mepivacaine—Body temperature increased—Carboplatin—urinary bladder cancer	0.00843	0.00862	CcSEcCtD
Mepivacaine—Hypertension—Mitomycin—urinary bladder cancer	0.00839	0.00858	CcSEcCtD
Mepivacaine—Asthenia—Valrubicin—urinary bladder cancer	0.00826	0.00844	CcSEcCtD
Mepivacaine—Pruritus—Valrubicin—urinary bladder cancer	0.00815	0.00833	CcSEcCtD
Mepivacaine—Oedema—Mitomycin—urinary bladder cancer	0.00793	0.00811	CcSEcCtD
Mepivacaine—Shock—Mitomycin—urinary bladder cancer	0.00781	0.00798	CcSEcCtD
Mepivacaine—Urinary retention—Thiotepa—urinary bladder cancer	0.00772	0.00789	CcSEcCtD
Mepivacaine—Cardiac arrest—Thiotepa—urinary bladder cancer	0.00772	0.00789	CcSEcCtD
Mepivacaine—Lidocaine—EGFR—urinary bladder cancer	0.00765	1	CrCbGaD
Mepivacaine—Dizziness—Valrubicin—urinary bladder cancer	0.00762	0.00778	CcSEcCtD
Mepivacaine—Swelling—Fluorouracil—urinary bladder cancer	0.00761	0.00778	CcSEcCtD
Mepivacaine—Vomiting—Valrubicin—urinary bladder cancer	0.00732	0.00748	CcSEcCtD
Mepivacaine—Headache—Valrubicin—urinary bladder cancer	0.00722	0.00737	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Gemcitabine—urinary bladder cancer	0.00706	0.00721	CcSEcCtD
Mepivacaine—Somnolence—Mitomycin—urinary bladder cancer	0.00705	0.00721	CcSEcCtD
Mepivacaine—Paralysis—Methotrexate—urinary bladder cancer	0.00693	0.00708	CcSEcCtD
Mepivacaine—Nausea—Valrubicin—urinary bladder cancer	0.00684	0.00699	CcSEcCtD
Mepivacaine—Swelling—Etoposide—urinary bladder cancer	0.00661	0.00676	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Cisplatin—urinary bladder cancer	0.00658	0.00672	CcSEcCtD
Mepivacaine—Paralysis—Epirubicin—urinary bladder cancer	0.00648	0.00662	CcSEcCtD
Mepivacaine—Cardiac arrest—Fluorouracil—urinary bladder cancer	0.00639	0.00652	CcSEcCtD
Mepivacaine—Body temperature increased—Mitomycin—urinary bladder cancer	0.00627	0.00641	CcSEcCtD
Mepivacaine—Ventricular arrhythmia—Epirubicin—urinary bladder cancer	0.00608	0.00622	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Etoposide—urinary bladder cancer	0.00603	0.00616	CcSEcCtD
Mepivacaine—Paralysis—Doxorubicin—urinary bladder cancer	0.006	0.00613	CcSEcCtD
Mepivacaine—Asthenia—Mitomycin—urinary bladder cancer	0.00569	0.00582	CcSEcCtD
Mepivacaine—Apnoea—Methotrexate—urinary bladder cancer	0.00568	0.0058	CcSEcCtD
Mepivacaine—Ventricular arrhythmia—Doxorubicin—urinary bladder cancer	0.00563	0.00575	CcSEcCtD
Mepivacaine—Cardiac arrest—Etoposide—urinary bladder cancer	0.00555	0.00567	CcSEcCtD
Mepivacaine—Sweating increased—Cisplatin—urinary bladder cancer	0.00536	0.00548	CcSEcCtD
Mepivacaine—Dizziness—Mitomycin—urinary bladder cancer	0.00525	0.00536	CcSEcCtD
Mepivacaine—Tinnitus—Thiotepa—urinary bladder cancer	0.00524	0.00535	CcSEcCtD
Mepivacaine—Sweating—Gemcitabine—urinary bladder cancer	0.00505	0.00516	CcSEcCtD
Mepivacaine—Vomiting—Mitomycin—urinary bladder cancer	0.00504	0.00516	CcSEcCtD
Mepivacaine—Chills—Thiotepa—urinary bladder cancer	0.00504	0.00515	CcSEcCtD
Mepivacaine—Headache—Mitomycin—urinary bladder cancer	0.00497	0.00508	CcSEcCtD
Mepivacaine—Sweating increased—Etoposide—urinary bladder cancer	0.00491	0.00502	CcSEcCtD
Mepivacaine—Erythema—Thiotepa—urinary bladder cancer	0.00489	0.005	CcSEcCtD
Mepivacaine—Tension—Thiotepa—urinary bladder cancer	0.0048	0.0049	CcSEcCtD
Mepivacaine—Nervousness—Thiotepa—urinary bladder cancer	0.00475	0.00485	CcSEcCtD
Mepivacaine—Back pain—Thiotepa—urinary bladder cancer	0.00473	0.00483	CcSEcCtD
Mepivacaine—Nausea—Mitomycin—urinary bladder cancer	0.00471	0.00482	CcSEcCtD
Mepivacaine—Atrioventricular block—Epirubicin—urinary bladder cancer	0.00464	0.00474	CcSEcCtD
Mepivacaine—Vision blurred—Thiotepa—urinary bladder cancer	0.00461	0.00471	CcSEcCtD
Mepivacaine—Agitation—Thiotepa—urinary bladder cancer	0.00449	0.00459	CcSEcCtD
Mepivacaine—Bradycardia—Cisplatin—urinary bladder cancer	0.00448	0.00458	CcSEcCtD
Mepivacaine—Atrioventricular block—Doxorubicin—urinary bladder cancer	0.0043	0.00439	CcSEcCtD
Mepivacaine—Chills—Gemcitabine—urinary bladder cancer	0.00424	0.00433	CcSEcCtD
Mepivacaine—Convulsion—Thiotepa—urinary bladder cancer	0.00424	0.00433	CcSEcCtD
Mepivacaine—Hypertension—Thiotepa—urinary bladder cancer	0.00422	0.00431	CcSEcCtD
Mepivacaine—Anxiety—Thiotepa—urinary bladder cancer	0.00415	0.00424	CcSEcCtD
Mepivacaine—Erythema—Gemcitabine—urinary bladder cancer	0.00411	0.0042	CcSEcCtD
Mepivacaine—Tinnitus—Cisplatin—urinary bladder cancer	0.00411	0.0042	CcSEcCtD
Mepivacaine—Erythema—Fluorouracil—urinary bladder cancer	0.00404	0.00413	CcSEcCtD
Mepivacaine—Back pain—Gemcitabine—urinary bladder cancer	0.00398	0.00407	CcSEcCtD
Mepivacaine—Tachycardia—Thiotepa—urinary bladder cancer	0.00389	0.00398	CcSEcCtD
Mepivacaine—Erythema—Cisplatin—urinary bladder cancer	0.00383	0.00392	CcSEcCtD
Mepivacaine—Vision blurred—Fluorouracil—urinary bladder cancer	0.00381	0.00389	CcSEcCtD
Mepivacaine—Chills—Etoposide—urinary bladder cancer	0.00362	0.0037	CcSEcCtD
Mepivacaine—Vision blurred—Cisplatin—urinary bladder cancer	0.00361	0.00369	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.00361	0.00369	CcSEcCtD
Mepivacaine—Tremor—Cisplatin—urinary bladder cancer	0.00359	0.00367	CcSEcCtD
Mepivacaine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00358	0.00366	CcSEcCtD
Mepivacaine—Hypertension—Gemcitabine—urinary bladder cancer	0.00355	0.00363	CcSEcCtD
Mepivacaine—Somnolence—Thiotepa—urinary bladder cancer	0.00355	0.00363	CcSEcCtD
Mepivacaine—Convulsion—Fluorouracil—urinary bladder cancer	0.0035	0.00358	CcSEcCtD
Mepivacaine—Back pain—Etoposide—urinary bladder cancer	0.0034	0.00347	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00338	0.00345	CcSEcCtD
Mepivacaine—Oedema—Gemcitabine—urinary bladder cancer	0.00336	0.00343	CcSEcCtD
Mepivacaine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00336	0.00343	CcSEcCtD
Mepivacaine—Convulsion—Cisplatin—urinary bladder cancer	0.00332	0.00339	CcSEcCtD
Mepivacaine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.0033	0.00337	CcSEcCtD
Mepivacaine—Oedema—Fluorouracil—urinary bladder cancer	0.0033	0.00337	CcSEcCtD
Mepivacaine—Anxiety—Cisplatin—urinary bladder cancer	0.00325	0.00332	CcSEcCtD
Mepivacaine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00324	0.00332	CcSEcCtD
Mepivacaine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00322	0.00329	CcSEcCtD
Mepivacaine—Urticaria—Thiotepa—urinary bladder cancer	0.00317	0.00324	CcSEcCtD
Mepivacaine—Body temperature increased—Thiotepa—urinary bladder cancer	0.00315	0.00322	CcSEcCtD
Mepivacaine—Hypotension—Gemcitabine—urinary bladder cancer	0.00314	0.00321	CcSEcCtD
Mepivacaine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00313	0.0032	CcSEcCtD
Mepivacaine—Oedema—Cisplatin—urinary bladder cancer	0.00313	0.0032	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.00313	0.00319	CcSEcCtD
Mepivacaine—Cardiac arrest—Epirubicin—urinary bladder cancer	0.00311	0.00318	CcSEcCtD
Mepivacaine—Loss of consciousness—Etoposide—urinary bladder cancer	0.00309	0.00315	CcSEcCtD
Mepivacaine—Hypotension—Fluorouracil—urinary bladder cancer	0.00308	0.00315	CcSEcCtD
Mepivacaine—Tachycardia—Cisplatin—urinary bladder cancer	0.00305	0.00312	CcSEcCtD
Mepivacaine—Convulsion—Etoposide—urinary bladder cancer	0.00304	0.00311	CcSEcCtD
Mepivacaine—Hypertension—Etoposide—urinary bladder cancer	0.00303	0.0031	CcSEcCtD
Mepivacaine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00302	0.00309	CcSEcCtD
Mepivacaine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00301	0.00308	CcSEcCtD
Mepivacaine—Somnolence—Gemcitabine—urinary bladder cancer	0.00298	0.00305	CcSEcCtD
Mepivacaine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00296	0.00303	CcSEcCtD
Mepivacaine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00294	0.003	CcSEcCtD
Mepivacaine—Somnolence—Fluorouracil—urinary bladder cancer	0.00293	0.003	CcSEcCtD
Mepivacaine—Hypotension—Cisplatin—urinary bladder cancer	0.00292	0.00299	CcSEcCtD
Mepivacaine—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.00288	0.00294	CcSEcCtD
Mepivacaine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00287	0.00293	CcSEcCtD
Mepivacaine—Asthenia—Thiotepa—urinary bladder cancer	0.00286	0.00293	CcSEcCtD
Mepivacaine—Pruritus—Thiotepa—urinary bladder cancer	0.00282	0.00288	CcSEcCtD
Mepivacaine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00281	0.00287	CcSEcCtD
Mepivacaine—Tachycardia—Etoposide—urinary bladder cancer	0.0028	0.00286	CcSEcCtD
Mepivacaine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00277	0.00283	CcSEcCtD
Mepivacaine—Drowsiness—Methotrexate—urinary bladder cancer	0.00269	0.00275	CcSEcCtD
Mepivacaine—Hypotension—Etoposide—urinary bladder cancer	0.00268	0.00274	CcSEcCtD
Mepivacaine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00265	0.00271	CcSEcCtD
Mepivacaine—Dizziness—Thiotepa—urinary bladder cancer	0.00264	0.0027	CcSEcCtD
Mepivacaine—Urticaria—Fluorouracil—urinary bladder cancer	0.00262	0.00268	CcSEcCtD
Mepivacaine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00261	0.00267	CcSEcCtD
Mepivacaine—Sweating—Methotrexate—urinary bladder cancer	0.00258	0.00264	CcSEcCtD
Mepivacaine—Paraesthesia—Etoposide—urinary bladder cancer	0.00257	0.00263	CcSEcCtD
Mepivacaine—Somnolence—Etoposide—urinary bladder cancer	0.00255	0.0026	CcSEcCtD
Mepivacaine—Vomiting—Thiotepa—urinary bladder cancer	0.00254	0.00259	CcSEcCtD
Mepivacaine—Drowsiness—Epirubicin—urinary bladder cancer	0.00252	0.00257	CcSEcCtD
Mepivacaine—Headache—Thiotepa—urinary bladder cancer	0.0025	0.00255	CcSEcCtD
Mepivacaine—Body temperature increased—Cisplatin—urinary bladder cancer	0.00247	0.00253	CcSEcCtD
Mepivacaine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00243	0.00248	CcSEcCtD
Mepivacaine—Sweating—Epirubicin—urinary bladder cancer	0.00242	0.00247	CcSEcCtD
Mepivacaine—Asthenia—Gemcitabine—urinary bladder cancer	0.00241	0.00246	CcSEcCtD
Mepivacaine—Pruritus—Gemcitabine—urinary bladder cancer	0.00237	0.00243	CcSEcCtD
Mepivacaine—Nausea—Thiotepa—urinary bladder cancer	0.00237	0.00242	CcSEcCtD
Mepivacaine—Pruritus—Fluorouracil—urinary bladder cancer	0.00233	0.00239	CcSEcCtD
Mepivacaine—Drowsiness—Doxorubicin—urinary bladder cancer	0.00233	0.00238	CcSEcCtD
Mepivacaine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00231	0.00236	CcSEcCtD
Mepivacaine—Bradycardia—Epirubicin—urinary bladder cancer	0.0023	0.00235	CcSEcCtD
Mepivacaine—Urticaria—Etoposide—urinary bladder cancer	0.00228	0.00233	CcSEcCtD
Mepivacaine—Body temperature increased—Etoposide—urinary bladder cancer	0.00227	0.00232	CcSEcCtD
Mepivacaine—Tinnitus—Methotrexate—urinary bladder cancer	0.00225	0.0023	CcSEcCtD
Mepivacaine—Asthenia—Cisplatin—urinary bladder cancer	0.00224	0.00229	CcSEcCtD
Mepivacaine—Sweating—Doxorubicin—urinary bladder cancer	0.00223	0.00228	CcSEcCtD
Mepivacaine—Dizziness—Fluorouracil—urinary bladder cancer	0.00218	0.00223	CcSEcCtD
Mepivacaine—Chills—Methotrexate—urinary bladder cancer	0.00217	0.00222	CcSEcCtD
Mepivacaine—Vomiting—Gemcitabine—urinary bladder cancer	0.00213	0.00218	CcSEcCtD
Mepivacaine—Bradycardia—Doxorubicin—urinary bladder cancer	0.00213	0.00218	CcSEcCtD
Mepivacaine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00211	0.00216	CcSEcCtD
Mepivacaine—Tinnitus—Epirubicin—urinary bladder cancer	0.00211	0.00215	CcSEcCtD
Mepivacaine—Erythema—Methotrexate—urinary bladder cancer	0.0021	0.00215	CcSEcCtD
Mepivacaine—Headache—Gemcitabine—urinary bladder cancer	0.0021	0.00215	CcSEcCtD
Mepivacaine—Vomiting—Fluorouracil—urinary bladder cancer	0.0021	0.00214	CcSEcCtD
Mepivacaine—Headache—Fluorouracil—urinary bladder cancer	0.00207	0.00211	CcSEcCtD
Mepivacaine—Asthenia—Etoposide—urinary bladder cancer	0.00206	0.0021	CcSEcCtD
Mepivacaine—Back pain—Methotrexate—urinary bladder cancer	0.00203	0.00208	CcSEcCtD
Mepivacaine—Chills—Epirubicin—urinary bladder cancer	0.00203	0.00207	CcSEcCtD
Mepivacaine—Pruritus—Etoposide—urinary bladder cancer	0.00203	0.00207	CcSEcCtD
Mepivacaine—Nausea—Gemcitabine—urinary bladder cancer	0.00199	0.00204	CcSEcCtD
Mepivacaine—Vomiting—Cisplatin—urinary bladder cancer	0.00199	0.00203	CcSEcCtD
Mepivacaine—Vision blurred—Methotrexate—urinary bladder cancer	0.00198	0.00203	CcSEcCtD
Mepivacaine—Erythema—Epirubicin—urinary bladder cancer	0.00197	0.00201	CcSEcCtD
Mepivacaine—Nausea—Fluorouracil—urinary bladder cancer	0.00196	0.002	CcSEcCtD
Mepivacaine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00195	0.00199	CcSEcCtD
Mepivacaine—Tension—Epirubicin—urinary bladder cancer	0.00193	0.00197	CcSEcCtD
Mepivacaine—Nervousness—Epirubicin—urinary bladder cancer	0.00191	0.00195	CcSEcCtD
Mepivacaine—Back pain—Epirubicin—urinary bladder cancer	0.0019	0.00195	CcSEcCtD
Mepivacaine—Dizziness—Etoposide—urinary bladder cancer	0.0019	0.00194	CcSEcCtD
Mepivacaine—Chills—Doxorubicin—urinary bladder cancer	0.00188	0.00192	CcSEcCtD
Mepivacaine—Nausea—Cisplatin—urinary bladder cancer	0.00186	0.0019	CcSEcCtD
Mepivacaine—Vision blurred—Epirubicin—urinary bladder cancer	0.00186	0.0019	CcSEcCtD
Mepivacaine—Convulsion—Methotrexate—urinary bladder cancer	0.00182	0.00186	CcSEcCtD
Mepivacaine—Vomiting—Etoposide—urinary bladder cancer	0.00182	0.00186	CcSEcCtD
Mepivacaine—Erythema—Doxorubicin—urinary bladder cancer	0.00182	0.00186	CcSEcCtD
Mepivacaine—Agitation—Epirubicin—urinary bladder cancer	0.00181	0.00185	CcSEcCtD
Mepivacaine—Headache—Etoposide—urinary bladder cancer	0.0018	0.00183	CcSEcCtD
Mepivacaine—Tension—Doxorubicin—urinary bladder cancer	0.00179	0.00183	CcSEcCtD
Mepivacaine—Nervousness—Doxorubicin—urinary bladder cancer	0.00177	0.00181	CcSEcCtD
Mepivacaine—Syncope—Epirubicin—urinary bladder cancer	0.00177	0.0018	CcSEcCtD
Mepivacaine—Back pain—Doxorubicin—urinary bladder cancer	0.00176	0.0018	CcSEcCtD
Mepivacaine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00173	0.00177	CcSEcCtD
Mepivacaine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.00172	0.00175	CcSEcCtD
Mepivacaine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00172	0.00175	CcSEcCtD
Mepivacaine—Convulsion—Epirubicin—urinary bladder cancer	0.00171	0.00174	CcSEcCtD
Mepivacaine—Nausea—Etoposide—urinary bladder cancer	0.0017	0.00174	CcSEcCtD
Mepivacaine—Hypertension—Epirubicin—urinary bladder cancer	0.0017	0.00174	CcSEcCtD
Mepivacaine—Agitation—Doxorubicin—urinary bladder cancer	0.00167	0.00171	CcSEcCtD
Mepivacaine—Anxiety—Epirubicin—urinary bladder cancer	0.00167	0.00171	CcSEcCtD
Mepivacaine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00166	0.0017	CcSEcCtD
Mepivacaine—Syncope—Doxorubicin—urinary bladder cancer	0.00163	0.00167	CcSEcCtD
Mepivacaine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.00161	0.00164	CcSEcCtD
Mepivacaine—Oedema—Epirubicin—urinary bladder cancer	0.00161	0.00164	CcSEcCtD
Mepivacaine—Hypotension—Methotrexate—urinary bladder cancer	0.0016	0.00164	CcSEcCtD
Mepivacaine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.0016	0.00164	CcSEcCtD
Mepivacaine—Shock—Epirubicin—urinary bladder cancer	0.00158	0.00162	CcSEcCtD
Mepivacaine—Convulsion—Doxorubicin—urinary bladder cancer	0.00158	0.00161	CcSEcCtD
Mepivacaine—Hypertension—Doxorubicin—urinary bladder cancer	0.00157	0.00161	CcSEcCtD
Mepivacaine—Tachycardia—Epirubicin—urinary bladder cancer	0.00157	0.0016	CcSEcCtD
Mepivacaine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00155	0.00159	CcSEcCtD
Mepivacaine—Anxiety—Doxorubicin—urinary bladder cancer	0.00155	0.00158	CcSEcCtD
Mepivacaine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00154	0.00158	CcSEcCtD
Mepivacaine—Somnolence—Methotrexate—urinary bladder cancer	0.00153	0.00156	CcSEcCtD
Mepivacaine—Hypotension—Epirubicin—urinary bladder cancer	0.0015	0.00153	CcSEcCtD
Mepivacaine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00149	0.00152	CcSEcCtD
Mepivacaine—Oedema—Doxorubicin—urinary bladder cancer	0.00149	0.00152	CcSEcCtD
Mepivacaine—Shock—Doxorubicin—urinary bladder cancer	0.00146	0.00149	CcSEcCtD
Mepivacaine—Tachycardia—Doxorubicin—urinary bladder cancer	0.00145	0.00148	CcSEcCtD
Mepivacaine—Paraesthesia—Epirubicin—urinary bladder cancer	0.00144	0.00147	CcSEcCtD
Mepivacaine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00144	0.00147	CcSEcCtD
Mepivacaine—Somnolence—Epirubicin—urinary bladder cancer	0.00143	0.00146	CcSEcCtD
Mepivacaine—Hypotension—Doxorubicin—urinary bladder cancer	0.00139	0.00142	CcSEcCtD
Mepivacaine—Urticaria—Methotrexate—urinary bladder cancer	0.00136	0.00139	CcSEcCtD
Mepivacaine—Body temperature increased—Methotrexate—urinary bladder cancer	0.00136	0.00139	CcSEcCtD
Mepivacaine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00133	0.00136	CcSEcCtD
Mepivacaine—Somnolence—Doxorubicin—urinary bladder cancer	0.00132	0.00135	CcSEcCtD
Mepivacaine—Urticaria—Epirubicin—urinary bladder cancer	0.00128	0.0013	CcSEcCtD
Mepivacaine—Body temperature increased—Epirubicin—urinary bladder cancer	0.00127	0.0013	CcSEcCtD
Mepivacaine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00126	0.00129	CcSEcCtD
Mepivacaine—Asthenia—Methotrexate—urinary bladder cancer	0.00123	0.00126	CcSEcCtD
Mepivacaine—Pruritus—Methotrexate—urinary bladder cancer	0.00121	0.00124	CcSEcCtD
Mepivacaine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00118	0.00121	CcSEcCtD
Mepivacaine—Urticaria—Doxorubicin—urinary bladder cancer	0.00118	0.00121	CcSEcCtD
Mepivacaine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.00118	0.0012	CcSEcCtD
Mepivacaine—Asthenia—Epirubicin—urinary bladder cancer	0.00115	0.00118	CcSEcCtD
Mepivacaine—Pruritus—Epirubicin—urinary bladder cancer	0.00114	0.00116	CcSEcCtD
Mepivacaine—Dizziness—Methotrexate—urinary bladder cancer	0.00114	0.00116	CcSEcCtD
Mepivacaine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.0011	0.00112	CcSEcCtD
Mepivacaine—Vomiting—Methotrexate—urinary bladder cancer	0.00109	0.00112	CcSEcCtD
Mepivacaine—Headache—Methotrexate—urinary bladder cancer	0.00108	0.0011	CcSEcCtD
Mepivacaine—Asthenia—Doxorubicin—urinary bladder cancer	0.00107	0.00109	CcSEcCtD
Mepivacaine—Dizziness—Epirubicin—urinary bladder cancer	0.00106	0.00109	CcSEcCtD
Mepivacaine—Pruritus—Doxorubicin—urinary bladder cancer	0.00105	0.00107	CcSEcCtD
Mepivacaine—Vomiting—Epirubicin—urinary bladder cancer	0.00102	0.00104	CcSEcCtD
Mepivacaine—Nausea—Methotrexate—urinary bladder cancer	0.00102	0.00104	CcSEcCtD
Mepivacaine—Headache—Epirubicin—urinary bladder cancer	0.00101	0.00103	CcSEcCtD
Mepivacaine—Dizziness—Doxorubicin—urinary bladder cancer	0.000983	0.001	CcSEcCtD
Mepivacaine—Nausea—Epirubicin—urinary bladder cancer	0.000954	0.000975	CcSEcCtD
Mepivacaine—Vomiting—Doxorubicin—urinary bladder cancer	0.000945	0.000966	CcSEcCtD
Mepivacaine—Headache—Doxorubicin—urinary bladder cancer	0.000931	0.000952	CcSEcCtD
Mepivacaine—Nausea—Doxorubicin—urinary bladder cancer	0.000883	0.000902	CcSEcCtD
Mepivacaine—SCN8A—L1CAM interactions—CNTN2—urinary bladder cancer	0.000687	0.0509	CbGpPWpGaD
Mepivacaine—SCN9A—L1CAM interactions—CNTN2—urinary bladder cancer	0.000555	0.0412	CbGpPWpGaD
Mepivacaine—SCN3A—L1CAM interactions—CNTN2—urinary bladder cancer	0.000531	0.0394	CbGpPWpGaD
Mepivacaine—SCN2A—L1CAM interactions—CNTN2—urinary bladder cancer	0.00051	0.0378	CbGpPWpGaD
Mepivacaine—SCN4A—L1CAM interactions—CNTN2—urinary bladder cancer	0.00051	0.0378	CbGpPWpGaD
Mepivacaine—SCN10A—L1CAM interactions—CNTN2—urinary bladder cancer	0.000492	0.0365	CbGpPWpGaD
Mepivacaine—SCN1A—L1CAM interactions—CNTN2—urinary bladder cancer	0.000492	0.0365	CbGpPWpGaD
Mepivacaine—SCN5A—L1CAM interactions—CNTN2—urinary bladder cancer	0.000346	0.0257	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—CNTN2—urinary bladder cancer	0.000259	0.0192	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—CNTN2—urinary bladder cancer	0.00021	0.0156	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—CNTN2—urinary bladder cancer	0.000201	0.0149	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—CNTN2—urinary bladder cancer	0.000193	0.0143	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—CNTN2—urinary bladder cancer	0.000193	0.0143	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—CNTN2—urinary bladder cancer	0.000186	0.0138	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—CNTN2—urinary bladder cancer	0.000186	0.0138	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—CNTN2—urinary bladder cancer	0.000185	0.0137	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—CNTN2—urinary bladder cancer	0.00015	0.0111	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—CNTN2—urinary bladder cancer	0.000143	0.0106	CbGpPWpGaD
Mepivacaine—SCN5A—Cardiac Progenitor Differentiation—IGF1—urinary bladder cancer	0.000142	0.0105	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—CNTN2—urinary bladder cancer	0.000138	0.0102	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—CNTN2—urinary bladder cancer	0.000138	0.0102	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—CNTN2—urinary bladder cancer	0.000133	0.00984	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—CNTN2—urinary bladder cancer	0.000133	0.00984	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—CNTN2—urinary bladder cancer	0.000131	0.0097	CbGpPWpGaD
Mepivacaine—SCN8A—L1CAM interactions—SRC—urinary bladder cancer	0.000117	0.00869	CbGpPWpGaD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000114	0.00844	CbGpPWpGaD
Mepivacaine—SCN8A—L1CAM interactions—EGFR—urinary bladder cancer	0.000103	0.00762	CbGpPWpGaD
Mepivacaine—SCN9A—L1CAM interactions—SRC—urinary bladder cancer	9.48e-05	0.00703	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—CNTN2—urinary bladder cancer	9.33e-05	0.00692	CbGpPWpGaD
Mepivacaine—SCN3A—L1CAM interactions—SRC—urinary bladder cancer	9.06e-05	0.00672	CbGpPWpGaD
Mepivacaine—SCN2A—L1CAM interactions—SRC—urinary bladder cancer	8.71e-05	0.00646	CbGpPWpGaD
Mepivacaine—SCN4A—L1CAM interactions—SRC—urinary bladder cancer	8.71e-05	0.00646	CbGpPWpGaD
Mepivacaine—SCN10A—L1CAM interactions—SRC—urinary bladder cancer	8.4e-05	0.00623	CbGpPWpGaD
Mepivacaine—SCN1A—L1CAM interactions—SRC—urinary bladder cancer	8.4e-05	0.00623	CbGpPWpGaD
Mepivacaine—SCN9A—L1CAM interactions—EGFR—urinary bladder cancer	8.31e-05	0.00616	CbGpPWpGaD
Mepivacaine—SCN3A—L1CAM interactions—EGFR—urinary bladder cancer	7.94e-05	0.00589	CbGpPWpGaD
Mepivacaine—SCN2A—L1CAM interactions—EGFR—urinary bladder cancer	7.63e-05	0.00566	CbGpPWpGaD
Mepivacaine—SCN4A—L1CAM interactions—EGFR—urinary bladder cancer	7.63e-05	0.00566	CbGpPWpGaD
Mepivacaine—SCN1A—L1CAM interactions—EGFR—urinary bladder cancer	7.36e-05	0.00546	CbGpPWpGaD
Mepivacaine—SCN10A—L1CAM interactions—EGFR—urinary bladder cancer	7.36e-05	0.00546	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—NCOR1—urinary bladder cancer	6.93e-05	0.00514	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—RHOA—urinary bladder cancer	6.05e-05	0.00449	CbGpPWpGaD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	6.04e-05	0.00448	CbGpPWpGaD
Mepivacaine—SCN5A—L1CAM interactions—SRC—urinary bladder cancer	5.9e-05	0.00438	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—NCOR1—urinary bladder cancer	5.6e-05	0.00416	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—ERBB2—urinary bladder cancer	5.6e-05	0.00415	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—CDK4—urinary bladder cancer	5.47e-05	0.00405	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—NCOR1—urinary bladder cancer	5.36e-05	0.00398	CbGpPWpGaD
Mepivacaine—SCN5A—L1CAM interactions—EGFR—urinary bladder cancer	5.17e-05	0.00384	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—NCOR1—urinary bladder cancer	5.15e-05	0.00382	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—NCOR1—urinary bladder cancer	5.15e-05	0.00382	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—PPARG—urinary bladder cancer	4.97e-05	0.00368	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—NCOR1—urinary bladder cancer	4.97e-05	0.00368	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—NCOR1—urinary bladder cancer	4.97e-05	0.00368	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—RHOA—urinary bladder cancer	4.89e-05	0.00363	CbGpPWpGaD
Mepivacaine—SCN9A—prostate gland—urinary bladder cancer	4.85e-05	0.169	CbGeAlD
Mepivacaine—SCN8A—Axon guidance—MMP9—urinary bladder cancer	4.8e-05	0.00356	CbGpPWpGaD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	4.8e-05	0.00356	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—CREBBP—urinary bladder cancer	4.77e-05	0.00354	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—RHOA—urinary bladder cancer	4.68e-05	0.00347	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—ERBB2—urinary bladder cancer	4.53e-05	0.00336	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—RHOA—urinary bladder cancer	4.49e-05	0.00333	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—RHOA—urinary bladder cancer	4.49e-05	0.00333	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—SRC—urinary bladder cancer	4.43e-05	0.00328	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—CDK4—urinary bladder cancer	4.42e-05	0.00328	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—RHOA—urinary bladder cancer	4.33e-05	0.00322	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—RHOA—urinary bladder cancer	4.33e-05	0.00322	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—ERBB2—urinary bladder cancer	4.33e-05	0.00321	CbGpPWpGaD
Mepivacaine—SCN4A—prostate gland—urinary bladder cancer	4.33e-05	0.151	CbGeAlD
Mepivacaine—SCN8A—Developmental Biology—RHOA—urinary bladder cancer	4.32e-05	0.0032	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—CDK4—urinary bladder cancer	4.23e-05	0.00314	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—ERBB2—urinary bladder cancer	4.16e-05	0.00309	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—ERBB2—urinary bladder cancer	4.16e-05	0.00309	CbGpPWpGaD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	4.12e-05	0.00305	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—CDK4—urinary bladder cancer	4.06e-05	0.00301	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—CDK4—urinary bladder cancer	4.06e-05	0.00301	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—PPARG—urinary bladder cancer	4.02e-05	0.00298	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—ERBB2—urinary bladder cancer	4.01e-05	0.00298	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—ERBB2—urinary bladder cancer	4.01e-05	0.00298	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—ERBB2—urinary bladder cancer	4e-05	0.00296	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—CDK4—urinary bladder cancer	3.92e-05	0.00291	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—CDK4—urinary bladder cancer	3.92e-05	0.00291	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—MMP9—urinary bladder cancer	3.88e-05	0.00288	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—EGFR—urinary bladder cancer	3.88e-05	0.00288	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—CREBBP—urinary bladder cancer	3.86e-05	0.00286	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—PPARG—urinary bladder cancer	3.84e-05	0.00285	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—MMP9—urinary bladder cancer	3.71e-05	0.00276	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—PPARG—urinary bladder cancer	3.69e-05	0.00274	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—PPARG—urinary bladder cancer	3.69e-05	0.00274	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—CREBBP—urinary bladder cancer	3.69e-05	0.00274	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—KRAS—urinary bladder cancer	3.67e-05	0.00272	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—SRC—urinary bladder cancer	3.58e-05	0.00266	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—MMP9—urinary bladder cancer	3.57e-05	0.00265	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—MMP9—urinary bladder cancer	3.57e-05	0.00265	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—PPARG—urinary bladder cancer	3.56e-05	0.00264	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—PPARG—urinary bladder cancer	3.56e-05	0.00264	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—CREBBP—urinary bladder cancer	3.55e-05	0.00263	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—CREBBP—urinary bladder cancer	3.55e-05	0.00263	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—NCOR1—urinary bladder cancer	3.49e-05	0.00259	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—RHOA—urinary bladder cancer	3.49e-05	0.00259	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—MMP9—urinary bladder cancer	3.44e-05	0.00255	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—MMP9—urinary bladder cancer	3.44e-05	0.00255	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—MMP9—urinary bladder cancer	3.43e-05	0.00254	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—SRC—urinary bladder cancer	3.43e-05	0.00254	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—CREBBP—urinary bladder cancer	3.42e-05	0.00254	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—CREBBP—urinary bladder cancer	3.42e-05	0.00254	CbGpPWpGaD
Mepivacaine—SCN3A—prostate gland—urinary bladder cancer	3.37e-05	0.118	CbGeAlD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	3.34e-05	0.00248	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—RHOA—urinary bladder cancer	3.34e-05	0.00248	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—SRC—urinary bladder cancer	3.29e-05	0.00244	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—SRC—urinary bladder cancer	3.29e-05	0.00244	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—EP300—urinary bladder cancer	3.25e-05	0.00241	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—ERBB2—urinary bladder cancer	3.23e-05	0.0024	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—RHOA—urinary bladder cancer	3.21e-05	0.00238	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—RHOA—urinary bladder cancer	3.21e-05	0.00238	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—SRC—urinary bladder cancer	3.17e-05	0.00235	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—SRC—urinary bladder cancer	3.17e-05	0.00235	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—SRC—urinary bladder cancer	3.16e-05	0.00234	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—EGFR—urinary bladder cancer	3.14e-05	0.00233	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—HRAS—urinary bladder cancer	3.12e-05	0.00231	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—RHOA—urinary bladder cancer	3.09e-05	0.00229	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—RHOA—urinary bladder cancer	3.09e-05	0.00229	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—ERBB2—urinary bladder cancer	3.09e-05	0.00229	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—RHOA—urinary bladder cancer	3.05e-05	0.00226	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—EGFR—urinary bladder cancer	3e-05	0.00223	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—ERBB2—urinary bladder cancer	2.97e-05	0.0022	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—ERBB2—urinary bladder cancer	2.97e-05	0.0022	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—KRAS—urinary bladder cancer	2.96e-05	0.0022	CbGpPWpGaD
Mepivacaine—SCN4A—renal system—urinary bladder cancer	2.95e-05	0.103	CbGeAlD
Mepivacaine—SCN4A—Axon guidance—EGFR—urinary bladder cancer	2.88e-05	0.00214	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—EGFR—urinary bladder cancer	2.88e-05	0.00214	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—ERBB2—urinary bladder cancer	2.86e-05	0.00212	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—ERBB2—urinary bladder cancer	2.86e-05	0.00212	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—KRAS—urinary bladder cancer	2.84e-05	0.0021	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—ERBB2—urinary bladder cancer	2.82e-05	0.00209	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—EGFR—urinary bladder cancer	2.78e-05	0.00206	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—EGFR—urinary bladder cancer	2.78e-05	0.00206	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—MMP9—urinary bladder cancer	2.77e-05	0.00206	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—EGFR—urinary bladder cancer	2.77e-05	0.00205	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—CDK4—urinary bladder cancer	2.75e-05	0.00204	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—KRAS—urinary bladder cancer	2.72e-05	0.00202	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—KRAS—urinary bladder cancer	2.72e-05	0.00202	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—MMP9—urinary bladder cancer	2.65e-05	0.00197	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—TNF—urinary bladder cancer	2.64e-05	0.00196	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—EP300—urinary bladder cancer	2.63e-05	0.00195	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—KRAS—urinary bladder cancer	2.63e-05	0.00195	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—KRAS—urinary bladder cancer	2.63e-05	0.00195	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—KRAS—urinary bladder cancer	2.62e-05	0.00194	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—SRC—urinary bladder cancer	2.56e-05	0.0019	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—MMP9—urinary bladder cancer	2.55e-05	0.00189	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—MMP9—urinary bladder cancer	2.55e-05	0.00189	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—HRAS—urinary bladder cancer	2.52e-05	0.00187	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—EP300—urinary bladder cancer	2.51e-05	0.00186	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—PPARG—urinary bladder cancer	2.5e-05	0.00186	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—MMP9—urinary bladder cancer	2.46e-05	0.00182	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—MMP9—urinary bladder cancer	2.46e-05	0.00182	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—SRC—urinary bladder cancer	2.44e-05	0.00181	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—MMP9—urinary bladder cancer	2.42e-05	0.00179	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—EP300—urinary bladder cancer	2.41e-05	0.00179	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—EP300—urinary bladder cancer	2.41e-05	0.00179	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—HRAS—urinary bladder cancer	2.41e-05	0.00179	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—CREBBP—urinary bladder cancer	2.4e-05	0.00178	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—SRC—urinary bladder cancer	2.35e-05	0.00174	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—SRC—urinary bladder cancer	2.35e-05	0.00174	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—EP300—urinary bladder cancer	2.33e-05	0.00173	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—EP300—urinary bladder cancer	2.33e-05	0.00173	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—HRAS—urinary bladder cancer	2.32e-05	0.00172	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—HRAS—urinary bladder cancer	2.32e-05	0.00172	CbGpPWpGaD
Mepivacaine—SCN3A—renal system—urinary bladder cancer	2.29e-05	0.0801	CbGeAlD
Mepivacaine—SCN1A—Developmental Biology—SRC—urinary bladder cancer	2.26e-05	0.00168	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—SRC—urinary bladder cancer	2.26e-05	0.00168	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—EGFR—urinary bladder cancer	2.24e-05	0.00166	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—HRAS—urinary bladder cancer	2.23e-05	0.00166	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—HRAS—urinary bladder cancer	2.23e-05	0.00166	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—SRC—urinary bladder cancer	2.23e-05	0.00165	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—HRAS—urinary bladder cancer	2.22e-05	0.00165	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—RHOA—urinary bladder cancer	2.17e-05	0.00161	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—EGFR—urinary bladder cancer	2.14e-05	0.00159	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—TNF—urinary bladder cancer	2.13e-05	0.00158	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—KRAS—urinary bladder cancer	2.12e-05	0.00157	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—EGFR—urinary bladder cancer	2.06e-05	0.00153	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—EGFR—urinary bladder cancer	2.06e-05	0.00153	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—TNF—urinary bladder cancer	2.04e-05	0.00151	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—KRAS—urinary bladder cancer	2.02e-05	0.0015	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—ERBB2—urinary bladder cancer	2.01e-05	0.00149	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—EGFR—urinary bladder cancer	1.98e-05	0.00147	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—EGFR—urinary bladder cancer	1.98e-05	0.00147	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—TNF—urinary bladder cancer	1.96e-05	0.00145	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—TNF—urinary bladder cancer	1.96e-05	0.00145	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—EGFR—urinary bladder cancer	1.96e-05	0.00145	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—KRAS—urinary bladder cancer	1.94e-05	0.00144	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—KRAS—urinary bladder cancer	1.94e-05	0.00144	CbGpPWpGaD
Mepivacaine—SCN2A—vagina—urinary bladder cancer	1.89e-05	0.066	CbGeAlD
Mepivacaine—SCN10A—Developmental Biology—TNF—urinary bladder cancer	1.89e-05	0.0014	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—TNF—urinary bladder cancer	1.89e-05	0.0014	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—KRAS—urinary bladder cancer	1.87e-05	0.00139	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—KRAS—urinary bladder cancer	1.87e-05	0.00139	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—KRAS—urinary bladder cancer	1.85e-05	0.00137	CbGpPWpGaD
Mepivacaine—SCN3A—female reproductive system—urinary bladder cancer	1.84e-05	0.0642	CbGeAlD
Mepivacaine—SCN9A—Developmental Biology—HRAS—urinary bladder cancer	1.8e-05	0.00133	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—MMP9—urinary bladder cancer	1.73e-05	0.00128	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—HRAS—urinary bladder cancer	1.72e-05	0.00128	CbGpPWpGaD
Mepivacaine—SCN3A—vagina—urinary bladder cancer	1.66e-05	0.058	CbGeAlD
Mepivacaine—SCN5A—vagina—urinary bladder cancer	1.66e-05	0.0579	CbGeAlD
Mepivacaine—SCN2A—Developmental Biology—HRAS—urinary bladder cancer	1.65e-05	0.00123	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—HRAS—urinary bladder cancer	1.65e-05	0.00123	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—EP300—urinary bladder cancer	1.64e-05	0.00121	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—HRAS—urinary bladder cancer	1.59e-05	0.00118	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—HRAS—urinary bladder cancer	1.59e-05	0.00118	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—SRC—urinary bladder cancer	1.59e-05	0.00118	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—HRAS—urinary bladder cancer	1.57e-05	0.00116	CbGpPWpGaD
Mepivacaine—SCN9A—lymph node—urinary bladder cancer	1.55e-05	0.0541	CbGeAlD
Mepivacaine—SCN5A—Developmental Biology—EGFR—urinary bladder cancer	1.4e-05	0.00104	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—TNF—urinary bladder cancer	1.33e-05	0.000986	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—KRAS—urinary bladder cancer	1.32e-05	0.000978	CbGpPWpGaD
Mepivacaine—SCN10A—lymph node—urinary bladder cancer	1.18e-05	0.0412	CbGeAlD
Mepivacaine—SCN5A—Developmental Biology—HRAS—urinary bladder cancer	1.12e-05	0.000831	CbGpPWpGaD
Mepivacaine—SCN3A—lymph node—urinary bladder cancer	1.08e-05	0.0375	CbGeAlD
